Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Clinical trial NCT00661427 · COMPLETED

Trial details

NCT number: NCT00661427
Sponsor: Memorial Sloan Kettering Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Cancer

Start date: 2007-11-01
Primary completion: 2012-08-01
Enrollment: 61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.